IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.030
-0.005 (-0.48%)
Aug 3, 2026, 1:29 PM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of March 31, 2026. The number of employees did not change compared to the same quarter last year.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,054,444
Market Cap
10.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 18 | 0 | - |
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Curis | 24 |
| BioCardia | 21 |
| Theriva Biologics | 16 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
INAB News
- 25 days ago - IN8bio therapy doubles progression free survival in brain cancer trial - TheFly
- 25 days ago - IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 2 months ago - IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies - GlobeNewsWire
- 2 months ago - IN8bio Slides: Corporate presentation - Filings
- 2 months ago - IN8bio announces updated INB-200, INB-400 study data - TheFly
- 2 months ago - IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 - GlobeNewsWire
- 2 months ago - IN8bio Transcript: R&D Day 2026 - Transcripts
- 2 months ago - IN8bio Slides: FY 2026 - Filings